Lilly Announces Positive Type 2 Diabetes Data

mia.burns Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly’s Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes Improvements ...

Eli Lilly plans low-cost launch strategy for new diabetes drugs

John Carroll As Lilly Diabetes President Enrique Conterno tells Bloomberg, the company plans to lean on its broad product portfolio to grow sales, rather than sending out legions of ...

Frost & Sullivan: Competition Intensifies as Pharma Companies Race to Launch Type 2 Diabetes Drugs

barbara.lempert Learn which products will eventually succeed and why, in the race against time LONDON – 28th August 2013 – The global pre-diabetes population is three times the ...

Pfizer, Sanford-Burnham in Diabetes Deal

barbara.lempert Sanford-Burnham Collaborates with Pfizer to Identify Targets for Treatment of Insulin Resistance and Diabetes LAKE NONA, FLA., August 13, 2013 – Sanford-Burnham ...

Array slashes staff after Amgen pulls the plug on diabetes drug pact

John Carroll Shares of Array BioPharma took a nasty dive Wednesday evening after Amgen pulled the plug on an ambitious four-year-old partnership to develop new Type 2 diabetes drugs. ...

After escape from Lilly’s graveyard, Type 1 diabetes drug promising in trial

John Carroll About three years after Eli Lilly threw in the towel on the late-stage Type 1 diabetes drug teplizumab, a pair of high-profile academic investigators says they have landed ...

Shire Launches Educational Resource for Diabetes

barbara.lempert Shire Launches Educational Resource for People Living with Diabetes and Their Caregivers HealTogether.com is designed to increase patient awareness of diabetic ...

GlaxoSmithKline hits speed bump en route to diabetes drug approval

Tracy Staton The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's Victoza and Bristol-Myers Squibb and AstraZeneca's ...

GlaxoSmithKline’s new diabetes drug faces delay at the FDA

John Carroll Glaxo says that the FDA asked for more time to review the information the big pharma company had submitted in response to the agency's queries and pushed back the deadline ...

Roundtable tackles NYC diabetes epidemic

mia.burns By Mia Burns The New York City Health Department and the health and wellness media company Everyday Health have released data alongside one another on diabetes in a city ...

FDA Decides No Risk Of Pancreatic Cancer With Diabetes Drugs

esilverman In yet another boost to several large drugmakers, the FDA has decided that there is no evidence that to confirm recent concerns that a widely used group of diabetes ...

CHMP Concludes Review of GLP-1-based diabetes therapies

mia.burns Investigation into GLP-1 based diabetes therapies concluded No new concerns for GLP-1 therapies identified on the basis of available evidence The European Medicines Agency’s ...
Page 4 of 8« First...23456...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS